Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review Viatris' Phase 3 trial for pimecrolimus 0.3% in blepharitis did not meet its primary goal, prompting the company to reassess its development strategy.
Viatris Eye Drops Data Shows Promise For Blurred Near Vision Viatris and Opus Genetics report MR-141 met efficacy and safety goals in Phase 3 VEGA-3 trial for presbyopia, with strong patient-reported benefits.
Unusual volume stocks in Tuesday's session Unusual volume stocks are being observed in Tuesday's session.
Discover the top movers in Friday's pre-market session. As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
